Genmab A/S (NASDAQ:GMAB) Rating Lowered to “Hold” at Wall Street Zen

Genmab A/S (NASDAQ:GMAB) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Friday.

Several other equities research analysts have also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Finally, Truist Financial dropped their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $39.17.

Genmab A/S Stock Up 1.8%

Shares of GMAB opened at $22.20 on Friday. The stock has a market capitalization of $14.23 billion, a P/E ratio of 12.76, a PEG ratio of 2.65 and a beta of 0.96. The firm has a fifty day simple moving average of $20.14 and a two-hundred day simple moving average of $20.67. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.56.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The business had revenue of $715.00 million during the quarter, compared to analysts’ expectations of $5.17 billion. Sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GMAB. Blue Trust Inc. increased its stake in shares of Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock worth $120,000 after acquiring an additional 1,442 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Genmab A/S by 229.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock valued at $1,033,000 after purchasing an additional 34,652 shares in the last quarter. ABC Arbitrage SA bought a new stake in Genmab A/S during the 4th quarter valued at about $3,692,000. Cromwell Holdings LLC increased its stake in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd increased its stake in Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock valued at $1,538,000 after purchasing an additional 58,048 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.